CD38 and Autoimmunity: Ongoing and upcoming clinical trials evaluating BCMA-targeted antibody–drug conjugates, anti-CD38 monoclonal antibodies, and chimeric antigen receptor (CAR) T-cell therapies are expected to substantially reshape treatment landscapes for refractory autoimmunity.